Evidence map›Paper›PMID 37066325›Full record

ArticleResearch square2023

Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination.

Nadège Nziza, Yixiang Deng, Lianna Wood, Navneet Dhanoa, Naomi Dulit-Greenberg, Tina Chen, Abigail Kane, Zoe Swank, Jameson Davis, Melina Demokritou and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Nadège NzizaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Yixiang DengRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Lianna WoodRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0001-9531-5627
Navneet DhanoaMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.ORCID 0000-0003-1020-8430
Naomi Dulit-GreenbergMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.
Tina ChenRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Abigail KaneMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.
Zoe SwankHarvard Medical School, Boston, MA, USA.
Jameson DavisMassachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA.ORCID 0000-0003-2530-2606
Melina DemokritouMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.
Anagha P ChitnisMassachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA.
Alessio FasanoMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.ORCID 0000-0002-2134-0261
Andrea G EdlowHarvard Medical School, Boston, MA, USA.ORCID 0000-0003-2915-5949
Nitya JainMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.
Bruce HorwitzMassachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA.ORCID 0000-0002-8123-8728
Ryan McNamaraRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Boris JulgRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0002-4687-9626
Wayne G ShrefflerMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Lael M YonkerMassachusetts General Hospital, Department of Pediatrics, Boston, MA, USA.ORCID 0000-0003-1711-8227
Harvard University · USMassachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · USBoston Children's Hospital · USBrigham and Women's Hospital · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
Research Project 2 The pregnancy AdaptOMEU19AI167899 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DOUGLAS A LAUFFENBURGER · 2022 to 2026
$14.7M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
Mechanistically Disentangling the Infected, Inflamed LungK08HL143183 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YONKER, LAEL · 2018 to 2022
$869k
NCI NIH HHS U01 CA260476NHLBI NIH HHS K08 HL143183NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI167899
6 · The paper itself

Abstract

Although young children generally experience mild symptoms following infection with SARS-CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines elicit robust immunoglobulin profiles in children ages 5 years and older, and in adults, corresponding with substantial protection against hospitalizations and severe disease. Whether similar immune responses and humoral protection can be observed in vaccinated infants and young children, who have a developing and vulnerable immune system, remains poorly understood. To study the impact of mRNA vaccination on the humoral immunity of infant, we used a system serology approach to comprehensively profile antibody responses in a cohort of children ages 6 months to 5 years who were vaccinated with the mRNA-1273 COVID-19 vaccine (25 μg). Responses were compared with vaccinated adults (100 μg), in addition to naturally infected toddlers and young children. Despite their lower vaccine dose, vaccinated toddlers elicited a stronger functional antibody response than adults, including against variant of concerns (VOCs), without report of side effects. Moreover, mRNA vaccination was associated with a higher IgG3-dependent humoral profile against SARS-CoV-2 compared to natural infection, supporting that mRNA vaccination is effective at eliciting a robust antibody response in toddlers and young children.

Identifiers

PMID37066325
PMCPMC10104253
OpenAlexW4362602883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.